Protalix BioTherapeutics to Hold Second Quarter 2020 Financial Results and Business Update Conference Call on August 10, 2020

Rhea-AI Summary

Protalix BioTherapeutics (NYSE: PLX) announced it will release its second quarter 2020 financial results and business update on August 10, 2020, at 8:30 a.m. EDT. A conference call with management will follow to discuss the results. Protalix, known for its ProCellEx® plant cell-based protein expression system, has developed recombinant therapeutic proteins, including taliglucerase alfa. The company has ongoing partnerships for product development, notably with Chiesi Farmaceutici for pegunigalsidase alfa aimed at Fabry disease.

Positive

• Upcoming Q2 2020 financial results expected to provide updates on performance and business outlook.
• Partnership with Chiesi Farmaceutici for pegunigalsidase alfa adds credibility to product development efforts.

Negative

• None.

CARMIEL, Israel, Aug. 3, 2020 /PRNewswire/Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx^® plant cell-based protein expression system, today announced that it will release its financial results for the second quarter 2020 and business update on Monday, August 10, 2020. The Company's management will host a conference call to discuss the financial results and provide a general business update at 8:30 a.m. Eastern Daylight Time (EDT).

 

 

Conference Call Details:
Monday, August 10, 2020, 8:30 a.m. Eastern Daylight Time (EDT)
Domestic: 877-423-9813
International: 201-689-8573
Conference ID: 13706783

Webcast Details:
Webcast Link: https://tinyurl.com/y3cuc7gw
Conference ID: 13706783

The conference call will also be broadcast live and available for replay for two weeks on the Company's website, www.protalix.com, in the Events Calendar of the Investors section. Please access the Company's website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix's unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.

Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.

Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human α–Galactosidase–A protein for the proposed treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.

Investor Contact
Chuck Padala, Managing Director
LifeSci Advisors
646-627-8390
chuck@lifesciadvisors.com

Media Contact
Brian Pinkston
LaVoieHealthScience
857-588-3347
bpinkston@lavoiehealthscience.com

View original content:http://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-hold-second-quarter-2020-financial-results-and-business-update-conference-call-on-august-10-2020-301104695.html

SOURCE Protalix BioTherapeutics, Inc.

FAQ

When will Protalix BioTherapeutics release its Q2 2020 financial results?

Protalix BioTherapeutics will release its Q2 2020 financial results on August 10, 2020.

What is the significance of the conference call scheduled for August 10, 2020?

The conference call will discuss Protalix's second quarter financial results and provide a business update.

What products are in Protalix's development pipeline?

Protalix's pipeline includes pegunigalsidase alfa for Fabry disease, OPRX-106 for anti-inflammation, and alidornase alfa for Cystic Fibrosis.

Who is involved in the development of pegunigalsidase alfa?

Protalix has partnered with Chiesi Farmaceutici for the development and commercialization of pegunigalsidase alfa.